Filing Flows › Industries › Health Care › Pharmaceutical Preparations
Pharmaceutical Preparations SIC 2834
261 companies filing with the SEC under SIC 2834. Median revenue growth +13% year on year in Q3 2026 (middle half -1% to +51%, 112 companies). The growth model expects the industry's combined revenue to grow +13% in Q3 2026. 80 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- BMY → MCK 36% of the supplier's revenue, $17.3B
- PFE → MCK 25% of the supplier's revenue, $15.6B
- BMY → COR 29% of the supplier's revenue, $14.0B
- BMY → CAH 22% of the supplier's revenue, $10.6B
- PFE → COR 16% of the supplier's revenue, $10.0B
- PFE → CAH 13% of the supplier's revenue, $8.1B
- BHC → COR 18% of the supplier's revenue, $1.8B
- BHC → MCK 16% of the supplier's revenue, $1.6B
- BHC → CAH 14% of the supplier's revenue, $1.4B
- ONC → MCK 18% of the supplier's revenue, $935M
- ALNY → NVS 23% of the supplier's revenue, $854M
- Keenova Therapeutics plc → COR 48% of the supplier's revenue, $680M
- Keenova Therapeutics plc → FFF Enterprises, Inc 46% of the supplier's revenue, $658M
- ELAN → COR 12% of the supplier's revenue, $566M
- ALKS → MCK 38% of the supplier's revenue, $561M
- PRGO → WMT 12% of the supplier's revenue, $506M
- ALKS → Mc Kesson Corporation 31% of the supplier's revenue, $458M
- JAZZ → MCK 10% of the supplier's revenue, $427M
- ALNY → REGN 11% of the supplier's revenue, $409M
- HRMY → CVS 38% of the supplier's revenue, $330M
- HRMY → Accredo Health Group, Inc 36% of the supplier's revenue, $313M
- IRWD → ABBV 99% of the supplier's revenue, $293M
- ALKS → COR 18% of the supplier's revenue, $266M
- HRMY → PANTHERx Specialty Pharmacy LLC 26% of the supplier's revenue, $226M
- PCRX → MCK 31% of the supplier's revenue, $225M
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +12.6% | $175.6B | $167.7B – $183.6B |
| Q4 2026 | +12.5% | $179.8B | $170.8B – $188.8B |
| Q1 2027 | +12.1% | $169.1B | $160.4B – $177.8B |
| Q2 2027 | +11.4% | $185.7B | $176.0B – $195.3B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| JNJ Johnson & Johnson | $25.4B | +6% | mature |
| LLY ELI Lilly | $24.4B | +39% | deceleration |
| MRK Merck | $18.1B | +5% | mature |
| ABBV AbbVie | $17.4B | +10% | transition |
| PFE Pfizer | $16.6B | -0.4% | mature |
| BMY Bristol Myers Squibb | $13.1B | +7% | mature |
| ABT Abbott Laboratories | $13.0B | +14% | transition |
| REGN Regeneron Pharmaceuticals | $5.1B | +36% | transition |
| TEVA Teva Pharmaceutical Industries | $4.4B | -2% | mature |
| VTRS Viatris | $3.7B | -0.3% | mature |
| VRTX Vertex Pharmaceuticals | $3.4B | +12% | transition |
| BHC Bausch Health Companies | $2.9B | +10% | mature |
| ZTS Zoetis | $2.4B | -1% | mature |
| ONC BeOne Medicines | $1.9B | +34% | transition |
| OGN Organon | $1.6B | -2% | mature |
| ALNY Alnylam Pharmaceuticals | $1.5B | +17% | deceleration |
| ELAN Elanco Animal Health | $1.3B | +11% | transition |
| JAZZ Jazz Pharmaceuticals | $1.2B | +10% | deceleration |
| BMRN BioMarin Pharmaceutical | $1.0B | +32% | transition |
| PRGO Perrigo | $989M | -5% | contraction |
| AMRX Amneal Pharmaceuticals | $863M | +10% | mature |
| UTHR United Therapeutics | $832M | +4% | mature |
| RPRX Royalty Pharma | $690M | +13% | transition |
| NRIX Nurix Therapeutics | $673M | 85× | reacceleration |
| INSM Insmed | $524M | +268% | deceleration |
| Keenova Therapeutics | $517M | — | deceleration |
| ALKS Alkermes | $480M | +22% | deceleration |
| MDGL Madrigal Pharmaceuticals | $431M | +50% | deceleration |
| PAHC Phibro Animal Health | $387M | +6% | mature |
| SRPT Sarepta Therapeutics | $381M | -5% | mature |
| PTCT PTC Therapeutics | $358M | +70% | deceleration |
| INDV Indivior Pharmaceuticals | $356M | +13% | transition |
| BBIO BridgeBio Pharma | $353M | +193% | expansion |
| ACAD Acadia Pharmaceuticals | $342M | +23% | transition |
| CORT Corcept Therapeutics | $340M | +64% | expansion |
| PBH Prestige Consumer Healthcare | $336M | +23% | reacceleration |
| ANIP ANI Pharmaceuticals | $291M | +28% | transition |
| KNSA Kiniksa Pharmaceuticals International | $286M | +58% | expansion |
| PTGX Protagonist Therapeutics | $274M | 58× | expansion |
| HRMY Harmony Biosciences Holdings | $269M | +12% | deceleration |
| IONS Ionis Pharmaceuticals | $268M | — | contraction |
| AXSM Axsome Therapeutics | $260M | +52% | expansion |
| TGTX TG Therapeutics | $240M | — | expansion |
| SUPN Supernus Pharmaceuticals | $227M | +18% | deceleration |
| TVTX Travere Therapeutics | $225M | +36% | deceleration |
| COLL Collegium Pharmaceutical | $216M | +3% | mature |
| VREOF Vireo Growth | $209M | — | expansion |
| AMPH Amphastar Pharmaceuticals | $208M | +8% | mature |
| MIRM Mirum Pharmaceuticals | $186M | +40% | transition |
| PCRX Pacira BioSciences | $177M | -2% | mature |
| RARE Ultragenyx Pharmaceutical | $173M | +8% | deceleration |
| LQDA Liquidia | $172M | — | deceleration |
| ARQT Arcutis Biotherapeutics | $144M | +45% | deceleration |
| IRWD Ironwood Pharmaceuticals | $133M | +9% | deceleration |
| ARDX Ardelyx | $128M | +16% | deceleration |
| NATR Natures Sunshine Products | $117M | -9% | contraction |
| XNCR Xencor | $117M | +455% | expansion |
| EBS Emergent BioSolutions | $110M | -52% | contraction |
| ZLAB Zai Lab | $108M | -7% | contraction |
| XERS Xeris Biopharma Holdings | $107M | +44% | transition |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.